MASS
BEARISH
$7.2
Live
908 Devices Inc. · NASDAQ
Target $10.0
(+38.9%)
$4.14
52W Range
$9.34
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$269.14M
P/E
N/A
ROE
-25.8%
Profit margin
34.7%
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
The company exhibits severe financial fragility, highlighted by a Piotroski F-Score of 1/9, indicating a critical lack of fundamental strength. While the balance sheet shows strong liquidity (Current Ratio 4.24) and minimal debt (Debt/Equity 0.03), these are offset by negative revenue growth (-7.70% YoY) and persistent operating losses. Insider sentiment is strongly bearish, with the CEO, CFO, and Directors selling shares amidst a long-term price collapse of 85.9% over five years. The disconnect between the high reported profit margin and the negative operating margin suggests non-operational gains rather than a sustainable business model.
Key Strengths
Strong short-term liquidity with a Current Ratio of 4.24
Very low leverage with a Debt/Equity ratio of 0.03
Healthy Gross Margins at 51.11%
Recent positive EPS surprises in the last few quarters
Relatively low Price-to-Book ratio of 1.82
Key Risks
Critical financial health failure as indicated by Piotroski F-Score (1/9)
Negative organic growth with YoY revenue declining by 7.70%
Negative operating margins (-17.30%) indicating an unsustainable cost structure
Aggressive insider selling by top executives (CEO and CFO)
Severe long-term capital erosion (-85.9% 5-year return)
AI Fair Value Estimate
Based on comprehensive analysis
$5.5
-23.6% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
20
Weak
35
30
15
20
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score, Revenue Decline, Insider Selling, Operating Losses
Confidence
90%
Value
35/100
P/S 4.79, Forward P/E -24.41
Positives
- Low P/B ratio
Watchpoints
- High P/S ratio (4.79) for a company with shrinking revenue
- Negative Forward P/E
Future
30/100
Revenue Growth -7.70%
Positives
- Recent EPS beats
Watchpoints
- Negative YoY Revenue Growth
- Negative Q/Q Revenue Growth
Past
15/100
5Y Change -85.9%
Positives
No standout positives identified.
Watchpoints
- Catastrophic 5-year price performance
- History of missing earnings estimates in 2021
Health
20/100
Piotroski F-Score 1/9
Positives
- Low Debt/Equity
- High Current Ratio
Watchpoints
- Piotroski F-Score 1/9
Dividend
0/100
Dividend Strength 0/100
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No dividend history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$7.2
Analyst Target
$10.0
Upside/Downside
+38.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MASS and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MASS
908 Devices Inc.
Primary
|
-85.9% | -13.6% | +62.9% | -8.5% | +18.6% | +5.1% |
|
CLPT
ClearPoint Neuro, Inc.
Peer
|
-59.8% | -1.5% | -17.2% | -65.6% | -21.4% | -0.3% |
|
EOLS
Evolus, Inc.
Peer
|
-69.9% | -50.5% | -56.3% | -34.1% | -23.6% | -5.1% |
|
CARL
Carlsmed, Inc.
Peer
|
-32.8% | -32.8% | -32.8% | -28.3% | -18.4% | +7.6% |
|
CHRS
Coherus Oncology, Inc.
Peer
|
-88.2% | -78.7% | +103.2% | -2.3% | -13.5% | -1.2% |
MAS
908 Devices Inc.
Primary
5Y
-85.9%
3Y
-13.6%
1Y
+62.9%
6M
-8.5%
1M
+18.6%
1W
+5.1%
CLP
ClearPoint Neuro, Inc.
Peer
5Y
-59.8%
3Y
-1.5%
1Y
-17.2%
6M
-65.6%
1M
-21.4%
1W
-0.3%
EOL
Evolus, Inc.
Peer
5Y
-69.9%
3Y
-50.5%
1Y
-56.3%
6M
-34.1%
1M
-23.6%
1W
-5.1%
CAR
Carlsmed, Inc.
Peer
5Y
-32.8%
3Y
-32.8%
1Y
-32.8%
6M
-28.3%
1M
-18.4%
1W
+7.6%
CHR
Coherus Oncology, Inc.
Peer
5Y
-88.2%
3Y
-78.7%
1Y
+103.2%
6M
-2.3%
1M
-13.5%
1W
-1.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-24.41
PEG Ratio
N/A
P/B Ratio
1.82
P/S Ratio
4.79
EV/Revenue
2.86
EV/EBITDA
-7.75
Market Cap
$269.14M
Profitability
Profit margins and return metrics
Profit Margin
34.68%
Operating Margin
-17.3%
Gross Margin
51.11%
ROE
-25.77%
ROA
-9.02%
Growth
Revenue and earnings growth rates
Revenue Growth
-7.7%
Earnings Growth
N/A
Q/Q Revenue Growth
-7.65%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
4.24
Strong
Quick Ratio
3.65
Excellent
Cash/Share
$3.02
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
52.7%
Op. Margin
-18.2%
Net Margin
24.0%
Total Assets
$0.2B
Liabilities
$0.0B
Equity
$0.1B
Debt/Equity
0.32x
Operating CF
$0.0B
Free Cash Flow
$0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-12
$N/A
2026-03-03
$0.02
+142.0% surprise
2025-11-10
$-0.04
+61.7% surprise
2025-08-05
$-0.37
-101.8% surprise
Healthcare Sector Comparison
Comparing MASS against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-25.77%
This Stock
vs
-86.0%
Sector Avg
-70.0%
(Below Avg)
Profit Margin
34.68%
This Stock
vs
-11.76%
Sector Avg
-394.9%
(Weaker)
Debt to Equity
0.03
This Stock
vs
3.51
Sector Avg
-99.1%
(Less Debt)
Revenue Growth
-7.7%
This Stock
vs
90.15%
Sector Avg
-108.5%
(Slower)
Current Ratio
4.24
This Stock
vs
3.67
Sector Avg
+15.8%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MASS
908 Devices Inc.
|
BEARISH | $269.14M | - | -25.8% | 34.7% | $7.2 | |
|
CLPT
ClearPoint Neuro, Inc.
|
BEARISH | $269.82M | - | -95.6% | -69.1% | $9.07 | Compare |
|
EOLS
Evolus, Inc.
|
NEUTRAL | $266.1M | - | -% | -17.4% | $4.09 | Compare |
|
CARL
Carlsmed, Inc.
|
NEUTRAL | $260.37M | - | -47.6% | -58.7% | $9.74 | Compare |
|
CHRS
Coherus Oncology, Inc.
|
NEUTRAL | $250.32M | - | -% | 398.4% | $1.67 | Compare |
MASS
908 Devices Inc.
BEARISH
Mkt Cap
$269M
P/E
-
ROE
-25.8%
Price
$7.2
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-10 | BROWN CHRISTOPHER D | Director | Sale | 40,000 | $282,278 |
| 2026-04-09 | MCCALLION KEVIN J PH.D. | Officer | Sale | 24,000 | $169,092 |
| 2026-04-09 | MCCALLION KEVIN J PH.D. | Officer | Option Exercise | 24,000 | $25,200 |
| 2026-03-02 | MCCALLION KEVIN J PH.D. | Officer | Sale | 7 | $49 |
| 2026-03-02 | MCCALLION KEVIN J PH.D. | Officer | Option Exercise | 7 | $7 |
| 2026-02-02 | GRIFFITH JOSEPH H. IV | Chief Financial Officer | Sale | 23,175 | $143,222 |
| 2026-02-02 | KNOPP KEVIN J | Chief Executive Officer | Sale | 34,764 | $214,842 |
| 2026-01-30 | GRIFFITH JOSEPH H. IV | Chief Financial Officer | Stock Award | 70,141 | - |
| 2026-01-30 | BROWN CHRISTOPHER D | Director | Stock Award | 23,437 | - |
| 2026-01-30 | KNOPP KEVIN J | Chief Executive Officer | Stock Award | 107,999 | - |
| 2025-12-30 | SPOTO MARK | Director | Gift | 928 | - |
BROWN CHRISTOPHER D
Director
2026-04-10
40,000 shares
·
$282,278
MCCALLION KEVIN J PH.D.
Officer
2026-04-09
24,000 shares
·
$169,092
MCCALLION KEVIN J PH.D.
Officer
2026-04-09
24,000 shares
·
$25,200
MCCALLION KEVIN J PH.D.
Officer
2026-03-02
7 shares
·
$49
MCCALLION KEVIN J PH.D.
Officer
2026-03-02
7 shares
·
$7
GRIFFITH JOSEPH H. IV
Chief Financial Officer
2026-02-02
23,175 shares
·
$143,222
KNOPP KEVIN J
Chief Executive Officer
2026-02-02
34,764 shares
·
$214,842
GRIFFITH JOSEPH H. IV
Chief Financial Officer
2026-01-30
70,141 shares
BROWN CHRISTOPHER D
Director
2026-01-30
23,437 shares
KNOPP KEVIN J
Chief Executive Officer
2026-01-30
107,999 shares
SPOTO MARK
Director
2025-12-30
928 shares
Insider transactions can signal confidence or concerns about company prospects
Past News Coverage
Recent headlines mentioning MASS from our newsroom.
Newest → oldest
No matching news yet.